Frankfurt
11.09.26 | 08:01
0,053 Euro
+3,95 % +0,002
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.08. | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January - June 2026 | 122 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, August 25, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), ("Isofol" or the "Company"), announced today that the company's interim report for January - June 2026 is... ► Artikel lesen | |
| 24.08. | Isofol Medical AB: Isofol expands the number of study sites to accelerate patient recruitment in cancer study | 160 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, August 24, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces that the company includes additional clinical trial sites to the ongoing phase Ib/II study with... ► Artikel lesen | |
| 08.07. | Isofol Medical AB: Isofol initiates last dose cohort in ongoing phase Ib study with arfolitixorin | 446 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, July 8, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has completed the third dose level in the dose-escalation part of the phase... ► Artikel lesen | |
| ISOFOL MEDICAL Aktie jetzt für 0€ handeln | |||||
| 19.05. | Isofol Medical AB: Bulletin from annual general meeting in Isofol Medical AB (publ) held on 19 May, 2026 | 452 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, May 19, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL) (the "Company") held its annual general meeting (the "AGM") today. The following resolutions, in principle, were... ► Artikel lesen | |
| 19.05. | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January - March 2026 | 212 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, May 19, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), ("Isofol" or the "Company"), announced today that the company's interim report for January - March 2026 is now... ► Artikel lesen | |
| 15.04. | Isofol Medical AB: Isofol optimizes the design of its phase Ib/II study following new regulatory approval | 539 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, April 15, 2026 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that the German regulatory authority BfArM has approved an optimized design for the company's... ► Artikel lesen | |
| 18.03. | Isofol Medical AB: Isofol secures license rights for arfolitixorin in autism | 825 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, March 18, 2026 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that the company has expanded its global exclusive license agreement for arfolitixorin to also... ► Artikel lesen | |
| 11.03. | Isofol Medical AB: Isofol receives top guarantee commitment and letters of intent corresponding to 42 percent of upcoming warrant exercise | 391 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, 11 March 2026 - Isofol Medical AB ("Isofol" or the "Company") announces today that the Company has received a top guarantee commitment from existing shareholder Solasia Pharma K.K.... ► Artikel lesen | |
| 24.02. | Isofol Medical AB: Isofol provides update on the ongoing phase Ib/II clinical study of arfolitixorin | 693 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, February 24, 2026 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today provides an update on the company's ongoing phase Ib/II clinical study of arfolitixorin, which is initially... ► Artikel lesen | |
| 18.02. | Isofol Medical AB: Isofol Medical AB (publ) publishes year-end report, January - December 2025 | 223 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, February 18, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), ("Isofol" or the "Company"), announced today that the company's year-end report for January - December 2025... ► Artikel lesen | |
| 13.11.25 | Isofol Medical AB: European Patent Office intends to grant a new patent for Isofol's arfolitixorin | 517 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, November 13 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the European Patent Office (EPO) has issued an Intention to Grant notice regarding a... ► Artikel lesen | |
| 12.11.25 | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January-September 2025 | 298 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, November 12, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), ("Isofol" or the "Company"), announced today that the company's interim report for January-September 2025... ► Artikel lesen | |
| 30.09.25 | Isofol Medical AB: Isofol's clinical study with arfolitixorin reaches another important milestone | 507 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, September 30, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has successfully completed the second dose level in the dose escalating... ► Artikel lesen | |
| 26.09.25 | Isofol Medical AB: Isofol completes transfer of shares to Solasia Pharma following a successful rights issue | 383 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, September 26, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the transfer of the shares subscribed by the Japanese collaboration partner Solasia... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,871 | -0,14 % | Valneva: Fortschritte bei Borreliose-Impfstoff geben langfristigem Potenzial Auftrieb | ||
| INTELLIA THERAPEUTICS | 10,160 | +0,40 % | Cathie Wood's ARK sells Twist Bioscience stock, buys more Intellia | ||
| SIRONA BIOCHEM | - | - | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 24.04.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 24.04.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 24.04.2026.ISIN NameCA46658Y1034 J2... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,796 | +4,42 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission | TORONTO, Sept. 10, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,099 | -2,05 % | PacBio Appoints Mark Van Oene as President and Chief Executive Officer | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions,... ► Artikel lesen | |
| ATAIBECKLEY | 6,250 | -0,79 % | Emyria vor Meilenstein: Erste Sydney-Klinik ist startbereit für Psychdelika-Patienten | ||
| BIOMERIEUX | 70,00 | 0,00 % | bioMérieux Highlights Positive Impacts of Rapid, Accurate Diagnostics for Patients and Accepts Industry Awards at ADLM 2026 | SALT LAKE CITY, Aug. 7, 2026 /PRNewswire/ -- bioMérieux, a world leader in the field of in vitro diagnostics, leveraged this year's 2026 Association for Diagnostics & Laboratory Medicine... ► Artikel lesen | |
| BIO GREEN MED SOLUTION | 0,853 | 0,00 % | Bio Green Med Solution, Inc. - S-4/A, Registration of securities, business combinations | ||
| ANAPTYSBIO | 47,400 | +1,98 % | Alphyn Capital on Its Special-Situation Investment: AnaptysBio (ANAB) | ||
| GENUS | 25,000 | -3,85 % | Genus Launches £60 Mln Share Buyback Programme | ||
| MEIRAGTX | 11,600 | +4,50 % | MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec) | MeiraGTx to receive up to $375 million in non-dilutive cash and up to $25 million in equity investmentFollowing regulatory approval, Oberland Capital to receive low single-digit capped royalties on... ► Artikel lesen | |
| AKESO | 9,950 | -0,30 % | Akeso, Inc.: Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive ... | HONG KONG, Sept. 2, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that a pre-specified interim analysis of overall survival... ► Artikel lesen | |
| ABIONYX PHARMA | 1,812 | 0,00 % | ABIONYX Pharma Reaches Another Key Milestone in the Industrialization of CER-001 by Entering into a Strategic Partnership with TEXCELL (ABL Diagnostics) for the Viral Safety and Clearance of Biologics | Preparation of validation batches for the CER-001 bioproduction process based on viral safety studies A key step in the industrial and regulatory dossier toward a future market launch for... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 1,920 | 0,00 % | XTL Biopharmaceuticals Ltd.: XTL Completed the Acquisition of Psyga Bio Ltd. | expands its IP portfolio to clinical-stage biopharmaceutical assets XTL Biopharmaceuticals (XTL) Completes the Acquisition of Psyga Bio and Establishes Psychedelic Biotechnology Platform At a historic... ► Artikel lesen | |
| MAAT PHARMA | 2,660 | 0,00 % | MaaT Pharma Presents the Results of its Annual General Meeting and Provides a Statement on its Half-Year Liquidity Contract | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen |
ISOFOL MEDICAL AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +3,95 % bei einem Aktienkurs von 0,053 Euro. Die Dividendendrendite beträgt aktuell 0,00 % (berechnet anhand der Ausschüttung von 0,00 Euro in den letzten 12 Monaten).
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ISOFOL MEDICAL AB finden Sie auf Wallstreet Online.